Computational inhibitor design against malaria plasmepsins

Cellular and Molecular Life Sciences

Volumn 64, Issue 17, 2007, Pages 2285-2305

  Bjelic, S ^a   Nervall, M ^a   Gutierrez de Teran H ^a   Ersmark, K ^a   Hallberg, A ^a   Aqvist J ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Inhibitor design; Linear interaction energy method; Malaria; Molecular dynamics; Plasmepsin; Reaction mechanism

Indexed keywords

PLASMEPSIN I; PLASMEPSIN II;

BACTERIAL STRAIN; BINDING AFFINITY; CRYSTAL STRUCTURE; DISEASE COURSE; DRUG TARGETING; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALARIA; MALARIA FALCIPARUM; REVIEW;

ANIMALS; ANTIMALARIALS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PLASMODIUM; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY;

EID: 34548348687     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7102-2     Document Type: Review

References (98)

1. Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y., and Hay, S. I. (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434, 214-217.
2. Baird, J. K. (2005) Drug therapy: effectiveness of antimalarial drugs. N. Engl. J. Med. 352, 1565-1577.
3. Targett, G. A. (2005) Malaria vaccines 1985-2005: a full circle? Trends Parasitol. 21, 499-503.
4. Greenwood, B., and Mutabingwa, T. (2002) Malaria in 2002. Nature 415, 670-672.
5. Greenwood, B. (2005) Malaria vaccines evaluation and implementation. Acta Trop. 95, 298-304.
6. Greenwood, B. M., Bojang, K., Whitty, C. J. M., and Targett, G. A. T. (2005) Malaria. Lancet 365, 1487-1498.
7. Miller, L. H., Baruch, D. I., Marsh, K., and Doumbo, O. K. (2002) The pathogenic basis of malaria. Nature 415, 673-679.
8. Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., Bassat, Q., Aide, P., Ofori-Anyinam, O., Navia, M. M., Corachan, S., Ceuppens, M., Dubois, M. C., Demoitie, M. A., Dubovsky, F., Menendez, C., Tornieporth, N., Ballou, W. R., Thompson, R., and Cohen, J. (2004) Efficacy of the RTS,S/ AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411-1420.
9. Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., Guinovart, C., Espasa, M., Corachan, S., Lievens, M., Navia, M. M., Dubois, M. C., Menendez, C., Dubovsky, F., Cohen, J., Thompson, R., and Ballou, W. R. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012-2018.
10. Biagini, G. A., Viriyavejakul, P., O'Neill, P. M., Bray, P. G., and Ward, S. A. (2006) Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob. Agents Chemother. 50, 1841-1851.
11. Mi-Ichi, F., Miyadera, H., Kobayashi, T., Takamiya, S., Waki, S., Iwata, S., Shibata, S., and Kita, K. (2005) Parasite mitochondria as a target of chemotherapy-inhibitory effect of licochalcone A on the Plasmodium falciparum respiratory chain. In: Natural Products and Molecular Therapy (Kotwal, G. J. and Lahiri, D. K., Eds.), pp 46-54, New York Academy of Sciences, New York.
12. Beitz, E. (2005) Aquaporins from pathogenic protozoan parasites: structure, function and potential for chemotherapy. Biol. Cell 97, 373-383.
13. Reguera, R. M., Tekwani, B. L., and Balana-Fouce, R. (2005) Polyamine transport in parasites: a potential target for new antiparasitic drug development. Comp. Biochem. Physiol. C Comp. Pharmacol. Toxicol. 140, 151-164.
14. Eastman, R. T., Buckner, F. S., Yokoyama, K., Gelb, M. H., and Van Voorhis, W. C. (2006) Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res. 47, 233-240.
15. Coppi, A., Cabinian, M., Mirelman, D., and Sinnis, P. (2006) Antimalarial activity of allicin, a biologically active compound from garlic cloves. Antimicrob. Agents Chemother. 50, 1731-1737.
16. Ersmark, K., Nervall, M., Gutierrez-de-Teran, H., Hamelink, E., Janka, L. K., Clemente, J. C., Dunn, B. M., Gogoll, A., Samuelsson, B., Åqvist, J., and Hallberg, A. (2006) Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg. Med. Chem. 14, 2197-2208.
17. Micale, N., Kozikowski, A. P., Ettari, R., Grasso, S., Zappala, M., Jeong, J. J., Kumar, A., Hanspal, M., and Chishti, A. H. (2006) Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. J. Med. Chem. 49, 3064-3067.
18. Yanow, S. K., Purcell, L. A., and Spithill, T. W. (2006) The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection. Mol. Biochem. Parasitol. 148, 52-59.
19. Goldberg, D. E., Slater, A. F., Beavis, R., Chait, B., Cerami, A., and Henderson, G. B. (1991) Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173, 961-9.
20. Liu, J., Gluzman, I. Y., Drew, M. E., and Goldberg, D. E. (2005) The role of Plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem. 280, 1432-1437.
21. Omara-Opyene, A. L., Moura, P. A., Sulsona, C. R., Bonilla, J. A., Yowell, C. A., Fujioka, H., Fidock, D. A., and Dame, J. B. (2004) Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279, 54088-54096.
22. Liu, J., Istvan, E. S., Gluzman, I. Y., Gross, J., and Goldberg, D. E. (2006) Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. USA. 103, 8840-8845.
23. Ersmark, K., Feierberg, I., Bjelic, S., Hulten, J., Samuelsson, B., Åqvist, J., and Hallberg, A. (2003) C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions. Bioorg. Med. Chem. 11, 3723-3733.
24. Nezami, A., Luque, I., Kimura, T., Kiso, Y., and Freire, E. (2002) Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry 41, 2273-2280.
25. Gohlke, H., and Klebe, G. (2002) Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed. 41, 2645-2676.
26. Jorgensen, W. L. (2004) Themany roles of computation in drug discovery. Science 303, 1813-1818.
27. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639-1662.
28. Ewing, T. J. A., and Kuntz, I. D. (1997) Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 18, 1175-1189.
29. Rarey, M., Kramer, B., Lengauer, T., and Klebe, G. (1996) A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261, 470-489.
30. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749.
31. Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., and Banks, J. L. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750-1759.
32. Jones, G., Willett, P., Glen, R. C., Leach, A. R., and Taylor, R. (1997) Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267, 727-748.
33. Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., and Taylor, R. D. (2003) Improved protein-ligand docking using GOLD. Proteins Struct. Funct. Genet. 52, 609-623.
34. Wang, R. X., Lu, Y. P., Fang, X. L., and Wang, S. M. (2004) An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J. Chem. Inf. Comput. Sci. 44, 2114-2125.
35. Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., and Mee, R. P. (1997) Empirical scoring functions. 1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 11, 425-445.
36. Wang, R. X., Lai, L. H., and Wang, S. M. (2002) Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput. Aided Mol. Des. 16, 11-26.
37. Velec, H. F. G., Gohlke, H., and Klebe, G. (2005) DrugScore(CSD)- knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction. J. Med. Chem. 48, 6296-6303.
38. Brandsdal, B. O., Österberg, F., Almlöf, M., Feierberg, I., Luzhkov, V. B., and Åqvist, J. (2003) Free energy calculations and ligand binding. Adv. Protein Chem. 66, 123-158.
39. Luzhkov, V. B., and Åqvist, J. (2001) Mechanisms of tetraethylammonium ion block in the KcsA potassium channel. FEBS Lett. 495, 191-6.
40. Åqvist, J., Medina, C., and Samuelsson, J. E. (1994) New method for predicting binding affinity in computer-aided drug design. Protein Eng. 7, 385-391.
41. Åqvist, J., and Marelius, J. (2001) The linear interaction energy method for predicting ligand binding free energies. Comb. Chem. High Throughput Screen. 4, 613-626.
42. Åqvist, J., Luzhkov, V. B., and Brandsdal, B. O. (2002) Ligand binding affinities from MD simulations. Acc. Chem. Res. 35, 358-365.
43. Huang, D., and Caflisch, A. (2004) Efficient evaluation of binding free energy using continuum electrostatics solvation. J. Med. Chem. 47, 5791-5797.
44. Tominaga, Y., and Jorgensen, W. L. (2004) General model for estimation of the inhibition of protein kinases using Monte Carlo simulations. J. Med. Chem. 47, 2534-2549.
45. Zhou, R. H., Friesner, R. A., Ghosh, A., Rizzo, R. C., Jorgensen, W. L., and Levy, R. M. (2001) New linear interaction method for binding affinity calculations using a continuumsolvent model. J. Phys. Chem. B 105, 10388-10397.
46. Zoete, V., Michielin, O., and Karplus, M. (2003) Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics: application to HIV-1 protease inhibitors. J. Comput. Aided Mol. Des. 17, 861-880.
47. Lee, F. S., Chu, Z. T., Bolger, M. B., and Warshel, A. (1992) Calculations of antibody-antigen interactions: microscopic and semi-microscopic evaluation of the free energies of binding of phosphorylcholine analogs to McPC603. Protein Eng. 5, 215-228.
48. Sham, Y., Chu, Z. T., Tao, H., and Warshel, A. (2000) Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA and PDLD/S-LRA calculations of ligands binding to an HIV protease. Proteins 39, 393-407.
49. Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S. H., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., and Cheatham, T. E. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889-897.
50. Carlsson, J., and Åqvist, J. (2006) Calculations of solute and solvent entropies from molecular dynamics simulations. Phys. Chem. Chem. Phys. 8, 5385-5395.
51. Ersmark, K., Feierberg, I., Bjelic, S., Hamelink, E., Hackett, F., Blackman, M. J., Hulten, J., Samuelsson, B., Åqvist, J., and Hallberg, A. (2004) Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J. Med. Chem. 47, 110-122.
52. Ersmark, K., Nervall, M., Hamelink, E., Janka, L. K., Clemente, J. C., Dunn, B. M., Blackman, M. J., Samuelsson, B., Åqvist, J., and Hallberg, A. (2005) Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J. Med. Chem. 48, 6090-6106.
53. Ersmark, K., Samuelsson, B., and Hallberg, A. (2006) Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. 26, 626-666.
54. Gutiérrez-de-Terán, H., Nervall, M., Ersmark, K., Dunn, B. M., Hallberg, A., and Åqvist, J. (2006) Inhibitor binding to the plasmepsin IVaspartic protease from Plasmodium falciparum. Biochemistry 45, 10529-10541.
55. Gutiérrez-de-Terán, H., Nervall, M., Dunn, B. M., Clemente, J. C., and Áqvist, J. (2006) Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor. FEBS Lett. 580, 5910-5916.
56. Haque, T. S., Skillman, A. G., Lee, C. E., Habashita, H., Gluzman, I. Y., Ewing, T. J. A., Goldberg, D. E., Kuntz, I. D., and Ellman, J. A. (1999) Potent, low-molecular-weight nonpeptide inhibitors of malarial aspartyl protease plasmepsin II. J. Med. Chem. 42, 1428-1440.
57. Graffner-Nordberg, M., Kolmodin, K., Åqvist, J., Queener, S. F., and Hallberg, A. (2004) Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. Eur. J. Pharm. Sci. 22, 43-54.
58. Graffner-Nordberg, M., Kolmodin, K., Åqvist, J., Queener, S. F., and Hallberg, A. (2001) Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. J. Med. Chem. 44, 2391-402.
59. Graffner-Nordberg, M., Marelius, J., Ohlsson, S., Persson, A., Swedberg, G., Andersson, P., Andersson, S. E., Åqvist, J., and Hallberg, A. (2000) Computational predictions of binding affinities to dihydrofolate reductase: synthesis and biological evaluation of methotrexate analogues. J. Med. Chem. 43, 3852-61.
60. Marelius, J., Graffner-Nordberg, M., Hansson, T., Hallberg, A., and Åqvist, J. (1998) Computation of affinity and selectivity: binding of 2,4-diaminopteridine and 2,4-diaminoquinazoline inhibitors to dihydrofolate reductases. J. Comput. Aided Drug Des. 12, 119-31.
61. Rizzo, R. C., Tirado-Rives, J., and Jorgensen, W. L. (2001) Estimation of binding affinities for HEPT and nevirapine analogues with HTV-1 reverse transcriptase via Monte Carlo simulations. J. Med. Chem. 44, 145-154.
62. Rizzo, R. C., Udier-Blagovic, M., Wang, D. P., Watkins, E. K., Smith, M. B. K., Smith, R. H., Tirado-Rives, J., and Jorgensen, W. L. (2002) Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. J. Med. Chem. 45, 2970-2987.
63. Rizzo, R. C., Wang, D. P., Tirado-Rives, J., and Jorgensen, W. L. (2000) Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles. J. Am. Chem. Soc. 122, 12898-12900.
64. Smith, R. H., Jorgensen, W. L., Tirado-Rives, J., Lamb, M. L., Janssen, P. A. J., Michejda, C. J., and Smith, M. B. K. (1998) Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J. Med. Chem. 41, 5272-5286.
65. Huang, D. Z., Luthi, U., Kolb, P., Cecchini, M., Barberis, A., and Caflisch, A. (2006) In silico discovery of beta-secretase inhibitors. J. Am. Chem. Soc. 128, 5436-5443.
66. Huo, S., Wang, J., Cieplak, P., Kollman, P. A., and Kuntz, I. D. (2002) Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design. J. Med. Chem. 45, 1412-1419.
67. Srinivasan, J., Cheatham, T. E., Cieplak, P., Kollman, P. A., and Case, D. A. (1998) Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J. Am. Chem. Soc. 120, 9401-9409.
68. Kuhn, B., and Kollman, P. A. (2000) Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J. Med. Chem. 43, 3786-3791.
69. Becker, O. M., Dhanoa, D. S., Marantz, Y., Chen, D. L., Shacham, S., Cheruku, S., Heifetz, A., Mohanty, P., Fichman, M., Sharadendu, A., Nudelman, R., Kauffman, M., and Noiman, S. (2006) An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J. Med. Chem. 49, 3116-3135.
70. Bjelic, S., and Åqvist, J. (2004) Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site. Biochemistry 43, 14521-14528.
71. Bjelic, S., and Åqvist, J. (2006) Catalysis and linear free energy relationships in aspartic proteases. Biochemistry 45, 7709-7723.
72. Coombs, G. H., Goldberg, D. E., Klemba, M., Berry, C., Kay, J., and Mottram, J. C. (2001) Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17, 532-537.
73. Banerjee, R., Liu, J., Beatty, W., Pelosof, L., Klemba, M., and Goldberg, D. E. (2002) Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA. 99, 990-995.
74. Dunn, B. M. (2002) Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. 102, 4431-4458.
75. Brik, A., and Wong, C. H. (2003) HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 1, 5-14.
76. Berry, C., Humphreys, M. J., Matharu, P., Granger, R., Horrocks, P., Moon, R. P., Certa, U., Ridley, R. G., Bur, D., and Kay, J. (1999) A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett. 447, 149-154.
77. Villa, J., and Warshel, A. (2001) Energetics and dynamics of enzymatic reactions. J. Phys. Chem. B 105, 7887-7907.
78. Åqvist, J., and Warshel, A. (1993) Simulation of enzymereactions using valence-bond force-fields and other hybrid quantum-classical approaches. Chem. Rev. 93, 2523-2544.
79. Friesner, R. A., and Guallar, V. (2005) Ab initio quantum chemical and mixed quantum mechanics/molecular mechanics (QM/MM) methods for studying enzymatic catalysis. Annu. Rev. Phys. Chem. 56, 389-427.
80. Schwede, T., Kopp, J., Guex, N., and Peitsch, M. C. (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385.
81. Boss, C., Richard-Bildstein, S., Weller, T., Fischli, W., Meyer, S., and Binkert, C. (2003) Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr. Med. Chem. 10, 883-907.
82. Prade, L., Jones, A. F., Boss, C., Bildstein, S. R., Meyer, S., Binkert, C., and Bur, D. (2005) X-ray structure of plasmepsin II complexed with a potent achiral inhibitor. J. Biol. Chem. 280, 23837-23843.
83. Hof, F., Schutz, A., Fah, C., Meyer, S., Bur, D., Liu, J., Goldberg, D. E., and Diederich, F. (2006) Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. Angew. Chem. Int. Ed. 45, 2138-2141.
84. Hulten, J., Bonham, N. M., Nillroth, U., Hansson, T., Zuccarello, G., Bouzide, A., Åqvist, J., Classon, B., Danielson, U. H., Karlen, A., Kvarnstrom, I., Samuelsson, B., and Hallberg, A. (1997) Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. J. Med. Chem. 40, 885-97.
85. Asojo, O. A., Afonina, E., Gulnik, S. V., Yu, B., Erickson, J. W., Randad, R., Medjahed, D., and Silva, A. M. (2002) Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 angstrom in complex with the inhibitors rs367 and rs370. Acta Crystallogr. D Biol. Crystallogr. D 58, 2001-2008.
86. Asojo, O. A., Gulnik, S. V., Afonina, E., Yu, B., Ellman, J. A., Haque, T. S., and Silva, A. M. (2003) Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J. Mol. Biol. 327, 173-181.
87. Bernstein, N. K., Cherney, M. M., Loetscher, H., Ridley, R. G., and James, M. N. G. (1999) Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum. Nat. Struct. Biol. 6, 32-37.
88. Silva, A. M., Lee, A. Y., Gulnik, S. V., Majer, P., Collins, J., Bhat, T. N., Collins, P. J., Cachau, R. E., Luker, K. E., Gluzman, I. Y., Francis, S. E., Oksman, A., Goldberg, D. E., and Erickson, J. W. (1996) Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA. 93, 10034-10039.
89. Tyndall, J. D. A., Reid, R. C., Tyssen, D. P., Jardine, D. K., Todd, B., Passmore, M., March, D. R., Pattenden, L. K., Bergman, D. A., Alewood, D., Hu, S. H., Alewood, P. F., Birch, C. J., Martin, J. L., and Fairlie, D. P. (2000) Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. J. Med. Chem. 43, 3495-3504.
90. Loughlin, W. A., Tyndall, J. D. A., Glenn, M. P., and Fairlie, D. P. (2004) Beta-strand mimetics. Chem. Rev. 104, 6085-6117.
91. Nezami, A., Kimura, T., Hidaka, K., Kiso, A., Liu, J., Kiso, Y., Goldberg, D. E., and Freire, E. (2003) High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 42, 8459-8464.
92. Westling, J., Yowell, C. A., Majer, P., Erickson, J. W., Dame, J. B., and Dunn, B. M. (1997) Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. Exp. Parasitol. 87, 185-193.
93. Bernstein, N. K., Cherney, M. M., Yowell, C. A., Dame, J. B., and James, M. N. (2003) Structural insights into the activation of P. vivax plasmepsin. J. Mol. Biol. 329, 505-524.
94. Clemente, J. C., Govindasamy, L., Madabushi, A., Fisher, S. Z., Moose, R. E., Yowell, C. A., Hidaka, K., Kimura, T., Hayashi, Y., Kiso, Y., Agbandje-McKenna, M., Dame, J. B., Dunn, B. M., and McKenna, R. (2006) Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr. D. Biol. Crystallogr. 62, 246-252.
95. Marelius, J., Hansson, T., and Åqvist, J. (1998) Calculation of ligand binding free energies from molecular dynamics simulations. Int. J. Quantum Chem. 69, 77-88.
96. Åqvist, J., and Hansson, T. (1996) On the validity of electrostatic linear response in polar solvents. J. Phys. Chem. 100, 9512-9521.
97. Miller, M., Schneider, J., Sathyanarayana, B. K., Toth, M. V., Marshall, G. R., Clawson, L., Selk, L., Kent, S. B. H., and Wlodawer, A. (1989) Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science 246, 1149-1152.
98. Kiso, A., Hidaka, K., Kimura, T., Hayashi, Y., Nezami, A., Freire, E., and Kiso, Y. (2004) Search for substrate-based inhibitors fitting the S-2′ space of malarial aspartic protease plasmepsin II. J. Pept. Sci. 10, 641-647.